Sparfosic acid (trisodium)

Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines[1][2][3].

Product Specifications

CAS Number

[70962-66-2]

UNSPSC

12352211

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sparfosic-acid-trisodium.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 180 mg/mL (ultrasonic) |H2O : 250 mg/mL (ultrasonic)

Smiles

O=C(O[Na])C[C@@H](C(O[Na])=O)NC(CP(O)(O[Na])=O)=O

Molecular Formula

C6H7NNa3O8P

Molecular Weight

321.06

References & Citations

[1]Wang J, et al. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug;47 (2) :782-90.|[2]Angela D. Morris, et al. A New, Efficient, Two Step Procedure for the Preparation of the Antineoplastic Agent Sparfosic Acid|[3]Johnson RK, et al. Antitumor activity of N- (phosphonacetyl) -L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res. 1976;36 (8) :2720-2725.|[4]Wadler S, et al. Phase II trial of N- (phosphonacetyl) -L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. Eur J Cancer. 1996;32A (7) :1254-1256.